Literature DB >> 11882390

In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting.

Matthew B Beard1, Elaine Huston, Lachlan Campbell, Irene Gall, Ian McPhee, Stephen Yarwood, Grant Scotland, Miles D Houslay.   

Abstract

The long cyclic AMP (cAMP)-specific phosphodiesterase isoform, PDE4A5 (PDE4A subfamily isoform variant 5), when transiently expressed in COS-7 cells, was shown in subcellular fractionation studies to be associated with both membrane and cytosol fractions, with immunofluorescence analyses identifying PDE4A5 as associated both with ruffles at the cell margin and also at a distinct perinuclear localisation. Deletion of the first nine amino acids of PDE4A5 (1) ablated its ability to interact with the SH3 domain of the tyrosyl kinase, LYN; (2) reduced, but did not ablate, membrane association; and (3) disrupted the focus of PDE4A5 localisation within ruffles at the cell margin. This deleted region contained a Class I SH3 binding motif of similar sequence to those identified by screening a phage display library with the LYN-SH3 domain. Truncation to remove the PDE4A5 isoform-specific N-terminal region caused a further reduction in membrane association and ablated localisation at the cell margin. Progressive truncation to delete the PDE4A long isoform common region and then the long isoform-specific UCR1 did not cause any further change in membrane association or intracellular distribution. However, deletion up to the super-short form splice junction generated an entirely soluble 'core' PDE4A species. We propose that multiple sites in the N-terminal noncatalytic portion of PDE4A5 have the potential to associate with intracellular structures and thus define its intracellular localisation. At least two such sites lie within the PDE4A5 isoform-specific N-terminal region and these appear to be primarily responsible for targeting PDE4A5 to, and organising it within, the cell margin; one is an SH3 binding motif able to interact with LYN kinase and the other lies within the C-terminal portion of the PDE4A5 unique region. A third membrane association region is located within the N-terminal portion of UCR2 and appears to be primarily responsible for targeting to the perinuclear region. Progressive N-terminal truncation, to delete defined regions of PDE4A5, identified activity changes occurring upon deletion of the SH3 binding site region and then upon deletion of the membrane association site region located within UCR2. This suggests that certain of these anchor sites may not only determine intracellular targeting but may also transduce regulatory effects on PDE4A5 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882390     DOI: 10.1016/s0898-6568(01)00264-9

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

1.  Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Authors:  Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

2.  AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa.

Authors:  Malini Bajpai; Sarah E Fiedler; Zaohua Huang; Srinivasan Vijayaraghavan; Gary E Olson; Gabriel Livera; Marco Conti; Daniel W Carr
Journal:  Biol Reprod       Date:  2005-09-21       Impact factor: 4.285

3.  The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s).

Authors:  Moses Xie; Brigitte Blackman; Colleen Scheitrum; Delphine Mika; Elise Blanchard; Tao Lei; Marco Conti; Wito Richter
Journal:  Biochem J       Date:  2014-05-01       Impact factor: 3.857

4.  Identification, characterization and subcellular localization of TcPDE1, a novel cAMP-specific phosphodiesterase from Trypanosoma cruzi.

Authors:  Maximiliano A D'Angelo; Santiago Sanguineti; Jeffrey M Reece; Lutz Birnbaumer; Héctor N Torres; Mirtha M Flawiá
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

Review 5.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

6.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 7.  Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides.

Authors:  Oliver Lomas; Manuela Zaccolo
Journal:  Physiology (Bethesda)       Date:  2014-03

Review 8.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.

Authors:  Lee Ann Johnston; Suat Erdogan; York Fong Cheung; Michael Sullivan; Rachael Barber; Martin J Lynch; George S Baillie; Gino Van Heeke; David R Adams; Elaine Huston; Miles D Houslay
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

Review 10.  A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool.

Authors:  Nahid Eskandari; Omid Mirmosayyeb; Gazaleh Bordbari; Reza Bastan; Zahra Yousefi; Alireza Andalib
Journal:  J Res Pharm Pract       Date:  2015 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.